The Department of Human Services (DHS) Office of Mental Health and Substance Abuse Services (OMHSAS) and Office of Developmental Programs (ODP) has announced a Statewide Quarterly Positive Approaches & Practices Virtual Meeting on October 12, 2023. It will be held from 10:00 am – 2:30 pm and will be regarding “Navigating Crisis Intervention in Human Services.” View the flyer for complete details.
This is a reminder that the Office of Developmental Programs (ODP) shared an announcement that provides eligible providers with the application to receive supplemental funds as part of the ongoing systemic recovery of services for people with an intellectual disability and autism. You can view the announcement here. Eligible providers who are interested in receiving these supplemental payments must complete the application and submit it to Rick Smith by September 30, 2023.
The Office of Developmental Programs (ODP) is notifying all interested stakeholders that the Centers for Medicaid and Medicare Services (CMS) has approved Pennsylvania’s Home and Community-Based Services (HCBS) Statewide Transition Plan. View the ODP announcement as well as the Statewide Transition Plan Infographic for details.
The Office of Developmental Programs (ODP) is providing information on the pending new annual submittal requirement of audited financial statements by qualified residential providers and supports coordination organizations. Please view the announcement for details.
The Office of Developmental Programs (ODP) has reached out to remind Medication Administration trainers that the 2004 paper course, as well as the 2004 and 2013 manuals, will be discontinued and no longer valid for use in training students after December 31, 2023. ODP also wishes to announce the Train-the-Trainer Fall 2023 Schedule. Read the full announcement for details.
The Office of Developmental Programs (ODP) has shared a new policy issued by the Pennsylvania Department of Education (PDE) that allows students who are eligible under federal IDEA to access a Free and Appropriate Public Education until their 22nd birthday. This means if a student would have traditionally exited from high school during or after the school term in which they turned 21 years of age, they now may remain in school until their 22nd birthday. This includes students that exited during or after the 2022/23 school term. Students can be reenrolled by contacting the school that the student will attend in the 2023/24 school term as soon as possible and requesting reenrollment.
If you have any questions or concerns, please contact your school district. If you require additional assistance from PDE, please send your request via email to PDE.
The Office of Developmental Programs (ODP) has shared a recent announcement that provides eligible providers with the application to receive supplemental funds as part of the ongoing systemic recovery of services for people with an intellectual disability and autism. You can view the announcement here. Eligible providers who are interested in receiving these supplemental payments must complete the application and submit it to Rick Smith by September 30, 2023.
The Office of Developmental Programs (ODP) has shared the following recall information announced by the U.S. Food and Drug Administration (FDA):
Dr. Berne’s Whole Health Products is recalling all lots of MSM DROPS 5% 15% Solution, Dr. Berne’s Organic Castor Oil Eye Drops, and Dr. Berne’s MSM MIST 15% Solution because FDA analysis has found one lot (lot 6786) of Dr. Berne’s MSM DROPS 5% Solution to fail sterility, with both bacterial and fungal contamination found in the product. Out of an abundance of caution, Dr. Berne’s is recalling all other lots of the 5% and 15% strengths of MSM Solution and all lots of Dr. Berne’s Organic Castor Oil Eye Drops and Dr. Berne’s MSM MIST 15% Solution. These products are used as lubricating eye drops.
RISK STATEMENT: Using contaminated eye drops could result in minor to serious vision-threatening infection, which could possibly progress to a life-threatening infection. To date, Dr. Berne’s has received 2 reports of adverse events related to this recall.
RECOMMENDATIONS:
Further information is available here.
Prev